CRTX - Why Cortexyme Stock Imploded in 2021
Shares of the central nervous system drug specialist Cortexyme (NASDAQ: CRTX) plummeted by a hefty 54% over the course of 2021, according to data provided by S&P Global Market Intelligence . The clinical-stage drugmaker 's shares imploded last year in response to the failure of its lead Alzheimer's disease candidate atuzaginstat in a combined phase 2/3 study.
Specifically, atuzaginstat reportedly missed both of its co-primary endpoints in the phase 2/3 Gain trial as a treatment for mild to moderate forms of Alzheimer's disease. However, the drug, which targets a bacterial infection in the brain of Alzheimer's disease patients, did show a promising dose-dependent response among individuals who tested positive for Porphyromonas gingivalis, a bacteria that causes the gum disease periodontitis.
Image source: Getty Images.
For further details see:
Why Cortexyme Stock Imploded in 2021